Identification of a subtype selective human PPARalpha agonist through parallel-array synthesis

Area of Science:

• Medicinal Chemistry
• Pharmacology
• Molecular Biology

Background:

• Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors that regulate gene expression involved in metabolism.
• Dyslipidemia is a major risk factor for cardiovascular disease, and PPARs are key targets for therapeutic intervention.

Purpose of the Study:

• To synthesize and evaluate novel urea-substituted thioisobutyric acids as potential modulators of human PPAR subtypes.
• To identify potent and selective agonists for PPARalpha with therapeutic potential for dyslipidemia.

Main Methods:

• Solid-phase, parallel-array synthesis was employed to generate a library of compounds.
• In vitro assays were performed to determine the activity and selectivity of synthesized compounds against human PPARalpha, PPARgamma, and PPARdelta.
• In vivo studies in animal models of dyslipidemia were conducted to assess lipid-lowering efficacy.

Main Results:

• GW7647 (compound 3) was identified as a highly potent human PPARalpha agonist.
• GW7647 demonstrated approximately 200-fold selectivity for PPARalpha over PPARgamma and PPARdelta.
• GW7647 exhibited potent lipid-lowering activity in animal models of dyslipidemia.

Conclusions:

• GW7647 is a potent and selective human PPARalpha agonist.
• GW7647 represents a valuable chemical tool for investigating PPARalpha biology in human cells and disease models.
• The findings support the therapeutic potential of PPARalpha agonists in treating dyslipidemia.